PP
IMGN

Paloma Partners’s Immunogen Inc IMGN Stock Holding History

Paloma Partners’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-51,400
Closed -$112K – 2367
2019
Q2 		$112K Buy
+51,400
New +$122K ﹤0.01% 1615
2018
Q2 		– Sell
-27,263
Closed -$287K – 2323
2018
Q1 		$287K Sell
27,263
-11,575
-30% -$114K ﹤0.01% 1643
2017
Q4 		$249K Buy
+38,838
New +$240K ﹤0.01% 1625
2017
Q1 		– Sell
-66,414
Closed -$135K – 2295
2016
Q4 		$135K Buy
+66,414
New +$133K ﹤0.01% 1888

Other funds holding IMGN

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Paloma Partners's IMGN Position: Q3 2019 in Review

Paloma Partners sold out of Immunogen Inc (IMGN) in Q3 2019, closing a stake of 51,400 shares — an estimated $112K sold.

Paloma Partners first reported a position in IMGN in Q4 2016 and held it in 4 quarters. The position peaked at $287K in Q1 2018. 189 funds tracked by Wall St. Rank hold IMGN as of Q3 2019.

  • Paloma Partners reported no remaining Immunogen Inc position as of Q3 2019 after selling out during the quarter.
  • Paloma Partners sold 51,400 Immunogen Inc shares in Q3 2019, an estimated $112K.
  • Paloma Partners first reported a position in Immunogen Inc in Q4 2016 and held it in 4 quarters.
  • Paloma Partners's Immunogen Inc position peaked at $287K in Q1 2018.
  • 189 funds tracked by Wall St. Rank held Immunogen Inc as of Q3 2019.

Based on Paloma Partners's 13F filing for Q3 2019, filed 14 Nov 2019.